Novo Nordisk to phase out key drug, insulin cos spot big biz opportunityNovo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the a...
Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brandNovo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They ...
- Pharma cos to hike insulin prices by up to 15%
Drug price regulator National Pharmaceutical Pricing Authority allows cos to up MRP of popular insulin brands by 15%.